Quantitative pp65-antigenemia assay for the prediction of human cytomegalovirus disease in HIV-infected patients

AIDS

Volumn 13, Issue 18, 1999, Pages 2533-2539

  Blank, Brian S N ^a,c   Meenhorst, Pieter L ^c   Weverling, Gerrit Jan ^a,b   Stout Zonneveld, Anneke A M ^c   Pauw, Wouter ^c   Mulder, Jan Willem ^c   Van Dijk, Willemien C ^c,e   Smits, Paul ^d   Lange, Joep M A ^a  

^a Natl AIDS Therapy Evaluation Centre   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Department of Internal Medicine ^*  (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

^e Deaconess Hospital   (Netherlands)

Author keywords

AIDS; Cytomegalovirus; HIV; pp65 antigenemia assay

Indexed keywords

CD4 ANTIGEN; VIRUS ANTIGEN;

ADULT; ARTICLE; ASSAY; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMED CONSENT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL; T LYMPHOCYTE;

ADULT; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PHOSPHOPROTEINS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; SURVIVAL ANALYSIS; VIRAL MATRIX PROTEINS;

EID: 0033395158     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199912240-00006     Document Type: Article

References (26)

1. 1. Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS), Ann Intern Med 1988, 108:585-59-4.
2. 2. Drew WL. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 1992, 14:608-615.
3. 3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
4. 4. Volberding PA, Deeks SG. Antiretroviral therapy for HIV infection: promises and problems. JAMA 1998, 279:1343-1344.
5. 5. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996, 334:1491-1497.
6. 6. Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. J Infect Dis 1998, 177:48-56.
7. 7. Mazzuli T, Rubin RH, Ferraro MJ, et al. Cytomegalovirus antigenemia: clinical correlations in transplant recipients and in persons with AIDS. J Clin Microbiol 1993, 31:2824-2827.
8. 8. Salzberger B, Franzen C, Fätkenheuer G, et al. CMV-antigenemia in peripheral blood for the diagnosis of CMV disease in HIV infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:365-369.
9. 9. Bek B, Boeckh M, Lepenies J, et al. High level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up. J Clin Microbiol 1996, 34:457-459.
10. 10. Podzamczer D, Ferrer E, Garcia A, et al. pp65 antigenemia as a marker of future CMV disease and mortality in HIV-infected patients. Scand J Infect Dis 1997, 29:223-227.
11. 11. Francisci D, Tosti A, Preziosi R, Baldelli F, Stagni G, Pauzulli S. Role of antigenemia assay in the early diagnosis and prediction of human cytomegalovirus organ involvement in AIDS patients. Eur J Clin Microbiol Infect Dis 1995, 14:498-503.
12. 12. Wetherill PE, Landry ML, Alcabes P, Friedland G. Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV+ patients with and without CMV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 12:33-37.
13. 13. Shinkai M, Bozette SA, Powderly W, Frame P, Spector SA. Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J Infect Dis 1997, 175:302-308.
14. 14. Bowen EF, Sabin CA, Wilson P, et al. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS 1997, 11:889-893.
15. 15. Rasmussen L, Morris S, Zipeto D, et al. Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J Infect Dis 1995, 171:177-182.
16. 16. Spector SA, Wong R, Hsia K, Pilcher M, Stempien MJ. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest 1998, 101:497-502.
17. 17. Francisci D, Tosti A, Baldelli F, Stagni G, Pauluzzi S. The pp65 antigenaemia test as a predictor of cytomegalovirus-induced end-organ disease in patients with AIDS. AIDS 1997, 11:1341-1345.
18. 18. Dodl KK, Jacobsen PH, Hofmann B, et al. Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. AIDS 1997, 11:F21-F28.
19. 19. Ljungman P, Plotkin SA. Workshop on CMV disease: definition, clinical severity scores and new syndromes. Scand J Infect Dis 1995, 99:87-89.
20. 20. Van der Bij W, Torensma R, van Son WJ, et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes. J Med Virol 1988, 25:179-188.
21. 21. The TH, van den Berg AP, Harmsen MC, van der Bij W, van Son WJ. The cytomegalovirus antigenemia assay: a plea for standardization. Scand J Infect Dis 1995, Suppl. 99:25-29.
22. 22. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998, 11:533-554.
23. 23. Lipson SM, Toro A, Lotlikar M, et al. Significance of leukocyte concentration in the performance of the quantitative cytomegalovirus (CMV) antigenemia assay. Clin Diagn Virol 1997, 8:151-158.
24. 24. St George K, Rinaldo CR Jr. Comparison of commercially available antibody reagents for the cytomegalovirus pp65 antigenemia assay. Clin Diagn Virol 1997, 7:147-152.
25. 25. Perez JL, Niubo J, Ardanuy C, et al. Comparison of three commercially available monoclonal antibodies directed against pp65 antigen for cytomegalovirus antigenemia assay. Diagn Microbiol Infect Dis 1995, 21:21-25.
26. 26. Schafer P, Tenschert W, Gutensohn K, Laufs R. Minimal effect of delayed sample processing on results of quantitative PCR for cytomegalovirus DNA in leukocytes compared to results of an antigenemia assay. J Clin Microbiol 1997, 35:741-744.